42 and older, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Subjective Overall ScorePrimary· 15 Minutes
Subjective Overall Score was assessed using the 0-100 visual analogue scale where 0=Extremely poor, cannot use lenses and 100=Excellent=Highly impressed with these lenses overall
Group
Value
95% CI
Lens 1
71.4
± 18.0
Lens 2
80.3
± 14.7
Subjective ComfortSecondary· 15 Minutes
Subjective Comfort Score was assessed using the 0-100 visual analogue scale where 0=Extremely uncomfortable, causes pain, cannot be tolerated and 100=Excellent, cannot be felt
Group
Value
95% CI
Lens 1
75.0
± 20.9
Lens 2
88.9
± 12.2
Subjective VisionSecondary· 15 Minutes
Subjective Vision Score (distance and near) was assessed using the 0-100 visual analogue scale where 0=Unacceptable, cannot be worn and 100=Excellent, unaware of any visual loss
Distance Vision
Group
Value
95% CI
Lens 1
72.3
± 17.1
Lens 2
78.4
± 15.8
Near Vision
Group
Value
95% CI
Lens 1
77.4
± 18.2
Lens 2
79.6
± 15.7
Sponsor's own description
The study objective was to gather short-term clinical performance data for two soft multifocal contact lenses.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CooperVision, Inc.
Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05794126.